Roquefort Therapeutics (LON:ROQ) Trading Down 8.2% – Should You Sell?

Roquefort Therapeutics plc (LON:ROQ) was down 8.2% during mid-day trading on Monday . The company traded as low as GBX 1.07 and last traded at GBX 1.07. Approximately 500,000 shares traded hands during mid-day trading, a decline of 41% from the average daily volume of 851,802 shares. The stock had previously closed at GBX 1.17.

Roquefort Therapeutics Stock Performance

The stock’s 50-day simple moving average is GBX 1.24 and its 200-day simple moving average is GBX 1.59. The stock has a market cap of £1.75 million, a price-to-earnings ratio of -1.70 and a beta of 0.05. The company has a current ratio of 0.79, a quick ratio of 3.07 and a debt-to-equity ratio of 12.37.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.